ERBB2 and breast carcinoma: Moreover, it should be noted that our dataset does not reflect the prevalence of breast tumor subtypes: the TNBC subtype accounts for 10–15% of all breast tumors, while the proportion of HER2-positive breast carcinomas is around 15–20%.